Caribou Biosciences to Participate in Upcoming Investor Conferences
Caribou Biosciences to Participate in Upcoming Investor Conferences
BERKELEY, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz, PhD, Caribou's president and chief executive officer, will participate in the following investor conferences:
加利福尼亚州伯克利，2024年11月20日（全球新闻网）——加勒比生物科学公司（纳斯达克：CRBU），一家领先的临床阶段CRISPR基因编辑生物制药公司，今天宣布公司总裁兼首席执行官瑞秋·哈尔维茨博士将参加以下投资者会议：
-
Citi's 2024 Global Healthcare Conference, Miami, FL
December 3, 2024, panel at 2:30 PM EST
Panel title: Cell therapies in autoimmune disorders
Webcast
- 花旗银行2024年全球医疗健康会议，迈阿密，佛罗里达州
2024年12月3日，面板讨论在东部标准时间下午2:30
讨论主题：自身免疫性疾病中的电芯治疗
网络直播
-
7th Annual Evercore ISI HealthCONx Conference, Coral Gables, FL
December 4, 2024, fireside chat at 10:25 AM EST
Webcast
- 第七届evercore ISI HealthCONx会议，科拉尔盖布尔斯，佛罗里达州
2024年12月4日，炉边聊天在东部标准时间上午10:25
网络直播
For more information, visit the Events page on Caribou's website. Webcasts will be available on the Caribou website for 30 days after the event.
欲了解更多信息，请访问Caribou网站上的活动页面。活动结束后，网络直播将在Caribou网站上提供30天。
About Caribou's novel next-generation CRISPR platform
CRISPR genome editing uses easily designed, modular biological tools to make DNA changes in living cells. There are two basic components of Class 2 CRISPR systems: the nuclease protein that cuts DNA and the RNA molecule(s) that guide the nuclease to generate a site-specific, double-stranded break, leading to an edit at the targeted genomic site. CRISPR systems are capable of editing unintended genomic sites, known as off-target editing, which may lead to harmful effects on cellular function and phenotype. In response to this challenge, Caribou has developed CRISPR hybrid RNA-DNA guides (chRDNAs; pronounced "chardonnays") that direct substantially more precise genome editing compared to all-RNA guides. Caribou is deploying the power of its chRDNA technology to carry out high efficiency multiple edits, to develop CRISPR-edited therapies.
关于Caribou的新一代CRISPR平台
CRISPR基因组编辑使用易于设计的、模块化的生物工具在活体细胞中进行DNA改变。Class 2 CRISPR系统有两个基本元素：切割DNA的核酸酶蛋白和RNA分子，它们指导核酸酶在特定的基因组位点上产生特异性的双链断裂，从而在目标基因组位点上发生编辑。CRISPR系统能够编辑称为“非靶向编辑”的意外基因组位点，这可能对细胞功能和表型产生有害影响。针对这一挑战，Caribou开发了CRISPR杂交RNA-DNA指南（chRDNA；发音为“夏多内”），相对于全RNA指南，它们可以更精确地定向基因组编辑。Caribou正在利用其chRDNA技术的威力进行高效率的多个编辑，并开发CRISPR编辑的治疗方案。
About Caribou Biosciences, Inc.
Caribou Biosciences is a clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company's genome-editing platform, including its Cas12a chRDNA technology, enables superior precision to develop cell therapies that are armored to potentially improve activity against disease. Caribou is advancing a pipeline of off-the-shelf cell therapies from its CAR-T platform as readily available treatments for patients with hematologic malignancies and autoimmune diseases. Follow us @CaribouBio and visit .
关于Caribou Biosciences, Inc。
Caribou Biosciences是一家临床阶段的CRISPR基因编辑生物医药公司，致力于为患有毁灭性疾病的患者开发变革性疗法。该公司的基因组编辑平台，包括其Cas12a chRDNA技术，具有超强的精度，可以开发针对疾病的细胞疗法。Caribou正在推进基于其CAR-t平台的一系列可用的供体细胞疗法，作为血液系统恶性肿瘤和自身免疫性疾病患者可用的治疗方法。关注我们@CaribouBio并访问。
Caribou Biosciences, Inc. contacts:
Investors:
Amy Figueroa, CFA
investor.relations@cariboubio.com
Caribou Biosciences，Inc.联系方式：
投资者:
Amy Figueroa，CFA
investor.relations@cariboubio.com
Media:
Peggy Vorwald, PhD
media@cariboubio.com
媒体:
Peggy Vorwald，PhD
media@cariboubio.com
译文内容由第三方软件翻译。
